Form 4: Omeros Director Thomas Cable Receives Annual Stock Option Grant

Omeros Corporation Director Thomas J. Cable was granted 15,000 stock options with an exercise price of $3.20 per share as part of the company's non-employee director compensation policy.

Summary

• Thomas J. Cable, a Director of Omeros Corporation (OMER), was granted 15,000 stock options.
• The transaction date for this grant was June 27, 2025.
• The exercise price for these stock options is $3.20 per share.
• The options will fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, contingent on Mr. Cable's continued service as a director.
• The expiration date for these stock options is June 27, 2035.
• This grant is an automatic annual stock option award, consistent with Omeros Corporation's non-employee director compensation policy, for directors who have served at least six months and will continue to serve after the annual meeting.

Sentiment

Score: 6

Explanation: The document reports a routine, expected compensation event for a director, which is generally neutral to slightly positive as it aligns director interests with shareholders. It does not contain significant new financial performance data or strategic shifts.

Positives

• The grant of stock options to a director helps align their financial interests with those of the shareholders, encouraging long-term value creation.
• The transaction is part of a pre-established, automatic compensation policy, indicating a structured approach to director remuneration.

Future Outlook

The stock options are subject to future vesting, which is contingent upon the director's continued service through the day before the 2026 annual meeting of shareholders.

Management Comments

• "Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock."
• "This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date."

Industry Context

The granting of stock options to non-employee directors is a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Omeros, serving as a standard component of executive and director compensation packages to align interests with shareholders.

Comparison to Industry Standards

• Annual stock option grants to non-employee directors are a standard compensation practice in the U.S. public company landscape, including biotech firms.
• The structure, including vesting conditions tied to continued service, is typical for such equity awards, aiming to retain directors and align their long-term interests with company performance.
• While the specific number of options (15,000) and exercise price ($3.20) are company-specific, the mechanism of an automatic annual grant based on a pre-defined policy is consistent with corporate governance best practices observed in comparable companies.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Thomas J. Cable, a Director of Omeros Corporation, constitutes a related party transaction as it involves compensation provided to a key management personnel.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Director (Thomas J. Cable): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The stock options are expected to vest on the day before the 2026 annual meeting of Omeros Corporation shareholders, provided the director continues to serve.

Key Dates

Keywords

Omeros Corporation, OMER, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance